[374] Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin: a randomized, placebo controlled crossover study. Diabetes Care 2000; 23: 349-53.
[375] Olsson J, Lindberg G, Gottsäter M, Lindwall K, Sjöstrand A, Tisell A, Melander A. Increased mortality in type 2 diabetic patients using sulfonylurea and metformin in combination: a population based observational study. Diabetologia 2000; 43: 558-60.
[376] Bailey CJ, Grant PJ, Evans M, deFine Olivarius N, Andreasen AH, Fowler PBS, Good CB, Turner RC, Holman R, Stratton I, Kerner W. The UK Prospective Diabetes Study Correspondence. Lancet 1998; 352: 1932-4.
[377] American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2000; 23 (suppl 1): S 27-31.
[378] Shapiro ET, Cauter E van, Tillil H, et al. Glyburide enhances the responsiveness of the β-cell to glucose but does not corect the abnormal patterns of insulin secretion in non insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989; 69: 571-6.
[379] Groop LC, Ratheiser K, Luzi L. Effect of sulfonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose response study. Acta Diabetol 1991; 28: 162-8.
[380] Groop L, Neugebauer G. Clinical pharmacology of sulfonylureas. In: Kuhlmann J, Puls W, editors, Oral antidiabetics. Berlin Heidelberg New York: Springer-Verlag; 1996: 199-262.
[381] Lotz N, Bachmann W. Kombinaiionstherapie. In: Mehnert H, Standl E, Usadel KH, editors. Diabetologie in Klinik und Praxis. Stuttgart New York: Thieme; 1999: 212-18.
[382] S 52 Sulfanylharnstoffe (orale Antidiabetika). In: Rote Liste 2002. Aulendorf: Editio Cantor Verlag 2002: 367-8.
[383] Forth W, Henschler D, Rummel W, Starke K, editors. Pharmakologie und Toxikologie, 7th ed. Berlin Oxford Heidelberg: Spektrum; 1996: 570.
[384] Oliver S, Ahmad S. Pharmacokinetics and bioavailability of repaglinide, a new oral antidiabetic agent for patients with type-2 diabetes [abstract]. Diabetologia 1997; 40 (suppl) A1260.
[385] Weaver ML, Orwig BA, Rodrigues LC, Graham ED, Chin JA, Shapiro MJ, McLeod JF, Mangold JB. Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos 2001; 29: 415-21.
[386] Fuhlendorf J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-51.
[387] Hu S, Wang S, Fanelli B, Bell PA, Dunning BE, Geisse S, Schmitz R, Boettcher BR. Pancreatic β-cell KATP channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharm Exper Ther 2000; 293: 444-52.
[388] Whitelaw DC, Clark PM, Smith JM, Nattrass M. Effects of the new oral hypoglycaemic agent nateglinide in insulin secretion in type 2 diabetes mellitus. Diabetes Med 2000; 17: 225-9.
[389] Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE. Importance of early insulin secretion. Comparison of nateglinide and glyburide in previous diet-treated patients with type 2 diabetes. Diabetes Care 2001; 24: 983-8.
[390] Massi-Benedetti M, Damsbo P. Pharmacology and clinical experience with repaglinide. Exp Opin Invest Drugs 2000; 9: 885-98.
[391] Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23: 1660-5.
[392] Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 2000; 23: 349-53.
[393] Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119-24.
[394] Day C. Thiazolidindiones: a new class of antidiabetic drugs. Diabet Med 1999; 16: 179-92.
[395] Matthaei S, Stumvoll M, Häring HU. Thiazolidindione (Insulinsensitizer): Neue Äspekte in der Therapie des Diabetes mellitus Typ 2. Dtsch Ârztebl 2001; 98: 912-8.
[396] Maegawa H, Tachikawa-Ide R, Ugi S, Iwanishi M, Egawa K, Kikkawa R, Shigeta Y, Kashiwagi A. Pioglitazone ameliorates highly glucose induced desensitation of insulin receptor kinase in rat 1 fibroblasts in culture. Biochem Biophys Res Commun 1993; 197: 1078-82.
[397] Sandouk T, Reda D, Hofmann C. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442 A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology 1993; 133: 352-9.
[398] Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ, Kirkham DM, Lister CA, Smith SA. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes: association with increased insulin binding and cell surface GLUT-4 as measured by photoaffinity labeling. Diabetes 1995; 44: 1087-92.
[399] Kawamori R, Matsuhisa M, Kinoshita J, Mochizuki K, Niwa M, Arisaka T, Ikeda M, Kubota M, Wada M, Kanda T, Ikebuchi M, Tohdo R, Yamasaki Y. AD-4833 Clamp-OGL Study Group: Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998; 41: 35-43.
[400] Ikeda T, Fujiyama K. The effect of pioglitazone on glucose metabolism and insulin uptake in the perfused liver and hindquarter of high-fructose-fed rats. Metabolism 1998; 47: 1152-5.
[401] DeVos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R, Haman LG, Staels B, Briggs MR, Auwerx J. Thiazolidindiones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 1996; 98: 1004-9.
[402] Kallen CB, Lazar MA. Antidiabetic thiazolidindiones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1996; 93: 5793-6.
[403] Digby JE, Montague CT, Sewter CP, Sanders L, wilkison WO, O'Rahilly S, Prins JB. Thiazolidindione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes 1998; 47; 138-41.
[404] Murase K, Odaka H, Suzuki M, Tayuki N, Ikeda H. Pioglitazone time dependently reduces tumor necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia 1998; 41: 257-64.
[405] Grossmann SL, Lessem J, Mechanism and clinical effects of thiazolidindiones. Expert Opin Invest Drug 1997; 6: 1025-40.
[406] Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegan EW, A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994; 43: 1203-10.
[407] Gomi-Berthold J, Berthold HK, Weber AA, Seul C, Vetter H, Sachinidis A. Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth. Exp Clin Endocrinol Diabetes 2001; 109: 203-9.
[408] Salzman A, Patel J. Rosiglitazone is not associated with hepatotoxicity [abstract], Diabetes 1999; 48 (suppl 1): A95.
[409] Ferman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Int Med 2000; 132: 118-21.
[410] Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient recieving rosiglitazone: a case report. Ann Intern Med 2000; 132: 121-4.
[411] Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure [letter]. Ann Intern Med 2000; 132: 164.
[412]
